1. 2013 ESH/ESC Guidelines for the management of arterial hypertension TheTask Force for the management ofarterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281–357.
2. Березин А.Е. Клиническая эффективность и безопасность применения олмесартана – нового антагониста рецепторов к ангиотензину II – у пациентов с артериальной гипертензией. http://www.umj.com.ua
3. Aoki H, Izumo S, Sadoshima J. Angiotensin II activates RhoA in cardiac myocytes: A critical role of RhoA in angiotensin II-induced premyofibril formation. Circ Res 1998; 82: 666–76.
4. Miura S, Kiya Y, Kanazawa T et al. Differential bonding interactions of inverse agonists of angiotensin II type 1 receptor in stabilizing the inactive state. Mol Endocrinol 2008; 22: 139–46.
5. Fabia MJ, Abdilla N, Oltra R et al. Antihypertensive activity of angiotensin II AT 1 receptor antagonists: a systematic review of studies with 24h ambulatory blood pressure monitoring. J Hypertens 2007; 25: 1327–36.
6. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol 2007; 
21 (2): 181–90.
7. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005; 5 (1): 41–50. Erratum in: Am J Cardiovasc Drugs 2005; 5 (3): 209.
8. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 2010; 375: 938–48.
9. Lea J, Greene T, Hebert L et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947–53.
10. De Zeeuw D, Remuzzi G, Parving HH et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921–7.
11. Schmieder RE, Mann JF, Schumacher H et al. Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 2011; 22: 1353–64.
12. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the rennin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008; 148: 30–48.
13. Menne J, Ritz E, Ruilope LM. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) Observational Follow-Up Study: Benefits of RAS Blockade With Olmesartan Treatment Are Sustained After Study Discontinuation. J Am Heart Assoc 2014.
14. Haller H, Ito S,  Jr Izzo JL et al. ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–17.
15. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J 2010; 31: 2837–40.
16. Elias MF, Wolf PA, D`Agostino et al. Untreated blood pressure level is inversely reated to cognitive functioning: the Framingham Study. Am J Epidemiol 1993; 138 (6): 353–64.
17. Tzourio C, Dufouil C, Ducimetiere P et al. Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging. Neurology 1999; 53 (9): 1948–52.
18. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001.
19. Шишкова В.Н. Профилактика деменции у пациентов с артериальной гипертензией. Трудный пациент. 2014; 4: 26–32.
20. Гаврилова С.И., Калын Я.Б. Социально-средовые факторы и состояние психического здоровья пожилого населения. Вестн. РАМН. 2002; 9: 15–20.
21. Ruitenberg A, Skoog I, Ott A et al. Blood pressure and risk of dementia: results from the Rotterdam study and the Gothenburg H-70 Study. Dement Geriatr Cogn Disord 2001.
22. Fournier A. Cerebroprotection Mediated by Angiotensin II. A Hypothesis Supported by Recent Randomized Clinical Trials. J Am Coll Cardiol 2004; 43 (8): 1343–8.
23. Danlof B, Devereux RB, Kieldsen SE et al. For the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): 
a randomised trial against atenolol. Lancet 2002; 
359: 995–1003.
24. Pelisch N, Hosomi N, Ueno M. Blockade of AT1 Receptors Protects the Blood-Brain Barrier and Improves Cognition in Dahl Salt-Sensitive Hypertensive Rats. Am J Hypertens 2011; 24: 362–8.
25. Mogi M, Tsukuda K. Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 2007; 53 (8): 899–905.
26. Чукаева И.И., Орлова Н.В., Спирякина Я.Г. и др. Особенности динамики С-реактивного белка и цитокиновой активности у больных инфарктом миокарда и ее влияние на исходы и прогноз заболевания. Вестн. РГМУ. 2013; 2: 14–9.
27. Inaba S, Iwai M, Furuno M et al. Continuous activation of renin-angiotensin system impairs cognitive function in renin/angiotensinogen transgenic mice. Hypertension 2009; 53: 356–62.
28. Fliser D, Buchholz K, Haller H et al. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 110: 1103–7.
29. Smith RD, Yokoyama H, Levy PJ et al. Non-invasive hemodynamic data reflect treatment effects on vascular remodeling. J Clin Hypertens 2007; 9: A145.

И.И.Чукаева, М.В.Соловьева, Н.В.Орлова, Я.Г.Спирякина

Кафедра поликлинической терапии №2 лечебного факультета ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава России, Москва